A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children-Reference-Cited by-同舟云学术

A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children

Published:2022-02-03 Issue: Volume: Page:1-14
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Mungall Bruce A.¹^ORCID,Hoet Bernard²^ORCID,Nieto Guevara Javier³^ORCID,Soumahoro Lamine²^ORCID

Affiliation:

1. GSK, Yongsan-gu, Seoul, South Korea

2. GSK, Avenue Fleming 20, Wavre, Belgium

3. GSK, Oceanía Business Plaza (Torre 1000, Piso 34), Panama City, Panama

Funder

GlaxoSmithKline Biologicals

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2022.2012455

Reference70 articles.

1. Cohen O, Knoll M, O’Brien K, et al. Pneumococcal conjugate vaccine (PCV) product assessment. [Cited 2021 Jan 19] Available from: https://www.jhsph.edu/ivac/wp-content/uploads/2018/05/pcv-product-assessment-april-25-2017.pdf.

2. The history of pneumococcal conjugate vaccine development: dose selection

3. A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus

4. Impact of 2+1 pneumococcal conjugate vaccine program in the province of Quebec, Canada

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Study of pediatric invasive pneumococcal disease in the 13-pneumococcal conjugated vaccine era;Diagnostic Microbiology and Infectious Disease;2024-12

2. Assessing the Impact of Pneumococcal Conjugate Vaccine Immunization Schedule Change From 3+0 to 2+1 in Australian Children: A Retrospective Observational Study;Clinical Infectious Diseases;2024-08-14

3. Development of semisynthetic saponin immunostimulants;Medicinal Chemistry Research;2024-05-18

4. Immunogenicity of Current and Next-Generation Pneumococcal Conjugate Vaccines in Children: Current Challenges and Upcoming Opportunities;Open Forum Infectious Diseases;2024-04-26

5. Potential serotype-specific effectiveness against IPD of pneumococcal conjugate vaccines V114 and PCV20 in children given a 2+1 dosing regimen;Expert Review of Vaccines;2024-04-09